HRT Financial’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

HRT Financial’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,024	Closed	-$16K	–	3625
2023 Q1	$16K	Sell	11,024 -1,840	-14%	-$2.48K	﹤0.01%	2209
2022 Q4	$12K	Buy	+12,864	New	+$17.3K	﹤0.01%	2211
2022 Q1	–	Sell	-163,097	Closed	-$760K	–	4119
2021 Q4	$760K	Buy	163,097 +153,013	+1,517%	+$957K	﹤0.01%	1366
2021 Q3	$85K	Sell	10,084 -916	-8%	-$12.9K	﹤0.01%	2942
2021 Q2	$180K	Buy	+11,000	New	+$222K	﹤0.01%	2431

HRT Financial's TCRR Position: Q2 2023 in Review

HRT Financial sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 11,024 shares — an estimated $16K sold.

HRT Financial first reported a position in TCRR in Q2 2021 and held it in 5 quarters. The position peaked at $760K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

HRT Financial reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 11,024 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $16K.
HRT Financial first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2021 and held it in 5 quarters.
HRT Financial's TCR2 Therapeutics Inc. Common Stock position peaked at $760K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.